Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

REGNRegeneron PharmaceuticalsRunning, no new patients

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Follicular Lymphoma (FL)

5Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 5 insiders sold shares within a month

    Since Nov 4, 2026 · was worth 5, fading over time

    +4.8
Worry score5

Score over time

Stage
Phase 3
Patients
733 (planned)
Started
Nov 14, 2023
Main results expected
Jul 29, 2029
Fully finished
Jul 29, 2029
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapy

    Measured over: Up to 35 days

  • Incidence of treatment-emergent adverse events (TEAEs) of odronextamab in combination with chemotherapy

    Measured over: Up to 2 years

  • Severity of TEAEs of odronextamab in combination with chemotherapy

    Measured over: Up to 2 years

  • Complete Response rate at 30 months (CR30) assessed by independent central review (ICR)

    Measured over: Up to 30 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT06097364 · record last updated 2026-02-06 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT06097364) ↗